A phase I clinical trial was conducted by the Sunnybrook team which showed that transient opening of the BBB with focused ultrasound enhanced the delivery of trastuzumab to breast cancer metastasis in the brains of HER-2 positive patients [230]. This evidence concerns the gene ERBB2 and breast cancer.